-
Mashup Score: 5Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma - 14 day(s) ago
Bispecific antibodies (BsAbs) create an immunologic synapse between T cells and malignant cells, via T-cell surface marker CD3 and a tumor cell surface marker, activating T cells to achieve tumor cell killing. B-cell maturation antigen (BCMA) × CD3-directed BsAbs show promising activity against multiple myeloma (Table 1). 1 Teclistamab is the first BCMA-BsAb approved by the European Medicines Agency and US Food and Drug Administration for relapsed/refractory multiple myeloma (RRMM). 2. Rates of Infection
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 27 day(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Vaccination in Multiple Myeloma: Review of Current Literature - 27 day(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 1 month(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Vaccination in Multiple Myeloma: Review of Current Literature - 1 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 2 month(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 3 month(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Vaccination in Multiple Myeloma: Review of Current Literature - 3 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 5 month(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Vaccination in Multiple Myeloma: Review of Current Literature - 5 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: General Medicine News, Hem/OncsTweet
Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma [Jan 30, 2023] @Eddie_Cliff et al. @JCO_ASCO https://t.co/3I1RX9IONX #mmsm #ImmunoOnc #IDonc https://t.co/aoO4GIiqZe